Health & Fitness
Fri, November 2, 2012Thu, November 1, 2012Wed, October 31, 2012Tue, October 30, 2012Mon, October 29, 2012Sun, October 28, 2012Fri, October 26, 2012Thu, October 25, 2012Wed, October 24, 2012Tue, October 23, 2012Mon, October 22, 2012Sun, October 21, 2012Sat, October 20, 2012Fri, October 19, 2012Thu, October 18, 2012Wed, October 17, 2012Tue, October 16, 2012Mon, October 15, 2012Sun, October 14, 2012Fri, October 12, 2012Thu, October 11, 2012Wed, October 10, 2012Tue, October 9, 2012Mon, October 8, 2012Sun, October 7, 2012Sat, October 6, 2012Fri, October 5, 2012ViroPharma To Release 2012 Third Quarter Financial Results On October 25, 2012
Published in Health and Fitness on Thursday, October 18th 2012 at 8:16 GMT by Market Wire
ViroPharma To Release 2012 Third Quarter Financial Results On October 25, 2012 -- EXTON, Pa., Oct. 18, 2012 /PRNewswire/ --
EXTON, Pa., Oct. 18, 2012 /PRNewswire/ -- ViroPharma Incorporated's (Nasdaq: [ VPHM ]) third quarter financial results for 2012 are expected to be released on Thursday, October 25, 2012 before the open of the U.S. financial markets.
The company will host a conference call and live audio webcast at 9:00 a.m. Eastern Time on the same day. During the conference call, ViroPharma management will discuss the 2012 third quarter financial results and other business.
The press release and the live webcast of the conference call will be accessible via ViroPharma's corporate website at [ http://www.viropharma.com ]. An audio archive will be available at the same address until November 15, 2012. To participate in the conference call, please dial (800) 874-4559 (domestic) and (302) 607-2019 (international). After placing the call, please tell the operator you wish to join the ViroPharma investor conference call.
About ViroPharma Incorporated
ViroPharma Incorporated is an international biopharmaceutical company committed to developing and commercializing novel solutions for physician specialists to address unmet medical needs of patients living with diseases that have few if any clinical therapeutic options. ViroPharma is developing a portfolio of therapeutics for rare and Orphan diseases including C1 esterase inhibitor deficiency, Friedreich's Ataxia, and adrenal insufficiency; and recurrent C. difficile infection (CDI). Our goal is to provide rewarding careers to employees, to create new standards of care in the way serious diseases are treated, and to build international partnerships with the patients, advocates, and health care professionals we serve. ViroPharma's commercial products address diseases including hereditary angioedema (HAE), seizures and C. difficile-associated diarrhea (CDAD); for full U.S. prescribing information on our products, please download the package inserts at [ http://www.viropharma.com/Products.aspx ]; the prescribing information for other countries can be found at [ www.viropharma.com ].
ViroPharma routinely posts information, including press releases, which may be important to investors in the investor relations and media sections of our company's web site, [ www.viropharma.com ]. The company encourages investors to consult these sections for more information on ViroPharma and our business.
SOURCE ViroPharma Incorporated
